1. Bray F, Ferlay J, Soerjomataram I et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 85 countries. CA Cancer J Clin. 2018;68(6):394-424. https://doi.org/10.3322/caac.21492
2. Мазуренко Н.Н., Цыганова И.В., Гагарин И.М., Чуев Ю.В., Мочальникова В.В., Коломейцева А.А., Горбунова В.А. Мутации EGFR и KRAS, важные для таргетной терапии немелкоклеточного рака легких. Молекулярная медицина. 2013;6. URL: https://cyberleninka.ru/article/n/mutatsii-egfr-i-krasvazhnye-dlya-targetnoy-terapii-nemelkokletochnogo-raka-legkih.
3. Duma N, Santana-Davila R, Molina JR. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clin Proc. 2019 Aug. 94(8):1623-1640. https://doi.org/10.1016/j.mayocp.2019.01.013. PMID: 31378236.
4. Моисеенко В.М., Проценко С.А., Семенов И.И. и др. Применение Ирессы (гефитиниба) в качестве терапии первой линии для лечения неоперабельных аденокарцином лёгкого, содержащих мутацию в гене EGFR. Современная онкология. 2010;12(1):74-80.
5. Shi Y et al. A prospective, molecular epidemiology study of EGFR mutations in asian patients with advanced non-small-cеll lung cаncеr of аdеnocаrcinomа histology (PIONЕЕR). J Thorac Oncol. 2014;9(2):154-162.
6. Огнерубов Н.А., Сычeв В.Д., Козловa Н.А., Чaнг В.Л. Молeкулярно-гeнeтический портрeт немeлкоклетoчногo рaка легких в Тамбовской области: региональный опыт. Современная oнколoгия. 2020;22(3):88-93. https://doi.org/10.26442/18151434.2020.3.200393
7. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer. 2002;94:1593-611.
8. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J.2000;19:3159-67.
9. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366:2-16.
10. Sergina NV, Moasser MM. The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med. 2007;13(12):527-34. https://doi.org/10.1016/j.molmed.2007.10.002
11. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New Engl J Med. 2004;350:2129-39.
12. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol. 2005;23:2513-20.
13. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169-81.
14. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958-67.
15. Когония Л.М., Губенко М.С., Ашхацава Т.И. Что мы знаем о молекулярно-биологических особенностях EGFR при глиобластомах и немелкоклеточном раке легких? Медицинский совет. 2022;16(9):126-130. https://doi.org/10.21518/2079-701X-2022-16-9-126-130
16. Carcereny, E., Morán, T., Capdevila, L. et al. The epidermal growth factor receptor (EGRF) in lung cancer. Transl Respir Med. 2015;3(1). https://doi.org/10.1186/s40247-015-0013-z
17. Cappuzzo F, Camidge DR, Varella-Garcia M. Is FISH floating or still swimming in the lung cancer ocean? Ann Oncol 2011;22(3):493-99
18. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical l ung cancer models. Oncogene. 2008;27(34):4702-11.
19. Mitsudomi T., Kosaka T., Endoh H., Horio Y., Hida T., Mori S. et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-smallcell lung cancer with postoperative recurrence. J. Clin. Oncol. 2005;23:2513-2520.
20. U.S. Food and Drug Administration. NDA/BLA multi-disciplinary review and evaluation: BLA 761210; RYBREVANT, amivantamab-vmjw. [accessed 2021 Nov 1].
21. Neijssen J, Cardoso RMF, Chevalier KM, Wiegman L, Valerius T, Anderson GM et al. Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET. J Biol Chem. 2021;296:100641. https://doi.org/10.1016/j.jbc.2021.10064